You will still be permitted to attend the adjourned Meeting in person at the offices of Loeb & Loeb
LLP, located at 345 Park Avenue, New York, NY 10154, United States of America.
Extension of Time to Reverse Redemptions
In connection with the Meeting adjournment, the Company has determined that it will allow shareholders who previously elected to redeem their Class A
ordinary shares who wish to reverse their redemption requests by their sending their reversal request to or having their brokers contact the Company’s transfer agent, Continental Stock Transfer & Trust Company, by email at
spacredemptions@continentalshare.com by 5:00 p.m. Eastern Time on June 19, 2023.
Additional Information
Important Information About the Extension and Where to Find It
The Company filed its Definitive Proxy Statement for the Meeting with the SEC on May 15, 2023 to consider and vote upon the Extension Proposal and other
matters, and, beginning on or about May 17, 2023, first mailed the Proxy Statement and other relevant documents to its shareholders as of the May 12, 2023 record date for the Meeting. The Company’s shareholders and
other interested persons are advised to read the Definitive Proxy Statement and any amendments thereto, as well as all other relevant materials filed or that will be filed with the SEC, in connection with the Company’s solicitation of proxies
for the Meeting to be held to approve, among other things, the Extension Proposal, because these documents will contain important information about the Company and the Extension Proposal. Shareholders may also obtain a copy of the
Definitive Proxy Statement, as well as other documents filed with the SEC regarding the Extension Proposal and other documents filed with the SEC by the Company, without charge, at the SEC’s website located at www.sec.gov or by directing a
request to the Company’s proxy solicitor, Morrow Sodali LLC, (800) 662-5200, email: IVCP@info.morrowsodali.com.
Participants in the Solicitation
The Company and
certain of its respective directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of the Company’s shareholders in connection with the
Extension. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of the Company’s shareholders in connection with the Extension is set forth in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2022 and the Definitive Proxy Statement and any amendments thereto that have been filed with the SEC. Investors and security holders may obtain
more detailed information regarding the names of the Company’s directors and executive officers in the Company’s most recent Annual Report on Form 10-K for the year ended
December 31, 2022, and other documents of the Company filed, or to be filed, from time to time with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests
are included in the Definitive Proxy Statement. Shareholders, potential investors and other interested persons should read the Definitive Proxy Statement carefully before making any voting or investment decisions. You may obtain free copies of these
documents from the sources indicated above.
Forward-Looking Statements
The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of the
“safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,”
“forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that
are not statements of historical matters, although not all forward-looking statements contain such identifying words. These forward-looking statements include, but are not limited to, statements regarding the issuance of the Class A Ordinary
Shares to the non-redeeming Shareholders, additional voting and non-redemption agreements, the amount of funds that will be in the Trust Account on
the date of the Meeting and the funds that will remain in the Trust Account following the Meeting and approval of the
3